Events

Investival Showcase Virtual w/ Jackie Hunter

External And Internal Convergence - A Cross-Sector Approach To Healthcare’s Biggest Challenges.

Wednesday, November 11 - 14:45 GMT

As health economies face challenges of improving outcomes while lowering cost, among many others, a cross-sector approach to health and care is vital. Alongside new biotechnologies and combination therapeutic approaches has come the rapid expansion of AI in multiple settings, new digital technologies and, importantly, the more tech-savvy and engaged patient, convergence is starting to make meaningful impacts. How is the industry developing new core digital capabilities, alliances, partnerships and innovative ways to drive better outcomes? 

  • In which ways are health and care industry leaders’ driving solutions to healthcare’s biggest challenges through different therapeutics, digital, and device combination approaches? 
  • To what extent and in which ways does external innovation fit into this picture for pharma companies like J&J? 
  • How can the wider industry work towards true and meaningful convergence to improve outcomes? 
  • How can this holistic approach and personalised medicine approaches go hand in hand? 

Panelists:

Melanie Senior, Writer and Analyst (moderator) 

Prabhu Velusami, Senior Director, New Ventures and Transactions, Johnson & Johnson 

Dan Vahdat, CEO, Huma 

Nikolaj Sorensen, CEO, Orexo 

Jackie Hunter, Board Director, BenevolentAI 

Eric Marcotulli, CEO, Elysium Health

Register →


Jackie Hunter
Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020